Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 27, 2026
Welltower (WELL) Q2 Earnings Preview: High Bar Set for Healthcare REIT Growth

Welltower (WELL) Q2 Earnings Preview: High Bar Set for Healthcare REIT Growth

Key Takeaways

  • Welltower is scheduled to report second-quarter 2026 results after the market closes on Monday, July 27, with a conference call set for Tuesday, July 28, at 9:00 a.m. ET.
  • Wall Street analysts expect normalized FFO (funds from operations — a key profitability metric for REITs that adds back depreciation and amortization to net income) of $1.55 per share, reflecting a 21.1% year-over-year increase.
  • Consensus revenue estimates stand at approximately $3.43 billion, which would represent a 34.5% jump from the same period last year.
  • The company enters this report with a four-quarter streak of beating FFO estimates, with an average surprise of roughly 2.5%.
  • Full-year 2026 normalized FFO guidance was raised to $6.21–$6.35 per share following the first quarter, setting a high bar for the back half of the year.
  • Investor sentiment remains broadly bullish, with the stock up more than 55% over the past 12 months, driven by demographic tailwinds and strong operational execution.

Why Welltower’s Q2 Report Matters

Welltower Inc., the largest publicly traded healthcare REIT by market capitalization, sits at the center of what many call the “silver economy” — the massive and growing market for senior housing and wellness services across the United States, Canada, and the United Kingdom. With a portfolio of more than 2,500 communities, WELL is a bellwether for how demographic trends translate into real estate cash flows. This Q2 report is especially important because it arrives against a backdrop of elevated investor expectations: the stock has rallied sharply, valuations are stretched by historical standards, and the company must demonstrate that its outsized same-store net operating income growth — which hit a record 16.4% in Q1 — remains sustainable heading into the second half of 2026. I also checked this using Tickeron’s AI Screener to see how WELL compares to others in the industry.

Earnings Expectations

Analysts have set a high bar for WELL’s second quarter. The Zacks Consensus Estimate for normalized FFO stands at $1.55 per share, which would mark a 21.1% improvement over the $1.28 reported in the year-ago quarter. Revenue expectations are similarly ambitious: the consensus calls for approximately $3.43 billion, implying year-over-year growth of roughly 34.5%. On a GAAP net income basis, consensus EPS estimates hover around $0.64 per share.

The company’s Seniors Housing Operating (SHO) portfolio is expected to remain the primary growth engine. In Q1, SHO same-store NOI surged 22.1%, driven by occupancy gains of roughly 370 basis points and solid revenue per occupied room (RevPOR) growth of approximately 5%. Analysts will be watching closely to see whether these occupancy and pricing trends continued in Q2, particularly given that muted new supply in senior housing has created a favorable operating environment. Interest income and other ancillary revenue streams — with consensus estimates of roughly $67 million and $30 million, respectively — will also be scrutinized for signs of diversification beyond core rental operations.

The company’s FY 2026 guidance, raised in April, calls for normalized FFO of $6.21 to $6.35 per diluted share and total portfolio same-store NOI growth of 12.25% to 16%. Q2 results will test whether the midpoint of that range remains achievable.

Market Reaction and Investor Sentiment

WELL shares have been on a remarkable run, gaining roughly 56.6% over the past 12 months and decisively outperforming both the S&P 500 and the broader real estate sector. The stock recently traded near $243, giving the company a market capitalization of approximately $170 billion. With a forward price-to-FFO multiple that some analysts consider rich, sentiment heading into this report is optimistic but carries an undercurrent of caution — the bar for a positive surprise is unusually high. From what I see in recent data, the four-quarter streak of beats adds some cushion, though the current Zacks Earnings ESP of -0.72% suggests the model is not strongly predicting another one.

Analyst coverage reflects this nuanced view. Of the 21 analysts following the stock, most rate it a Buy or Strong Buy, with a consensus price target around $237. However, Barclays initiated coverage with an Equal Weight rating and a $254 target in early July, signaling that not everyone sees compelling upside from current levels. Key risk factors heading into the print include elevated interest expenses, integration costs from recent acquisitions, and any signs of deceleration in same-store NOI growth.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should pay close attention to several forward-looking indicators embedded in WELL’s Q2 release and conference call.

First, occupancy trends in the SHO portfolio will be a major focus. The company gained approximately 370 basis points of occupancy in Q1, and any continuation — or pullback — in that trajectory will directly shape the outlook for same-store NOI growth in the second half of 2026. Communities operating at 95% or higher occupancy delivered roughly 20% NOI growth in Q1, underscoring the operating leverage embedded in the portfolio as utilization rates normalize.

Second, capital allocation activity deserves scrutiny. WELL closed $3.2 billion in investments during Q1 2026 alone, with year-to-date volumes reaching $10.5 billion. Management also signaled that an additional $7.3 billion in deals were either closed or under contract. The pace and pricing of this deployment — and whether the company continues funding it primarily through equity issuance and dispositions — will have meaningful implications for per-share growth metrics.

Third, the balance sheet remains a point of strength but also a potential sensitivity. Net debt to adjusted EBITDA stood at 2.73x as of March 31, 2026, and available liquidity totaled roughly $11.1 billion. Management has targeted a year-end leverage ratio of approximately 3.0x. Any movement above or below that range could influence how the market assesses WELL’s financial flexibility in a shifting interest rate environment.

Finally, the company’s emerging asset-light initiatives — including the external licensing of its data science platform and its $2.5 billion seniors housing fund — represent a newer dimension of the WELL story. While still modest contributors to current earnings, these fee-based revenue streams could, over time, alter the company’s growth profile and reduce its reliance on balance-sheet-intensive expansion.

Enhancing Research with Tickeron’s AI Tools

I frequently use Tickeron’s AI Screener when preparing for earnings seasons. It helps me quickly filter healthcare REITs, compare key metrics against peers, and spot stocks meeting specific technical or fundamental conditions ahead of reports like this one. The platform has become a practical part of my workflow for identifying trends in sectors with strong demographic drivers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WELL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


WELL's Stochastic Oscillator slumps oversold zone

The Stochastic Oscillator for WELL moved into oversold territory on August 11, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WELL advanced for three days, in of 350 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 303 cases where WELL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for WELL moved out of overbought territory on July 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WELL as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for WELL turned negative on July 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

WELL moved below its 50-day moving average on August 11, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WELL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

WELL broke above its upper Bollinger Band on July 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. WELL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.509) is normal, around the industry mean (3.219). WELL has a moderately high P/E Ratio (101.350) as compared to the industry average of (48.329). Projected Growth (PEG Ratio) (3.660) is also within normal values, averaging (3.232). WELL has a moderately low Dividend Yield (0.013) as compared to the industry average of (0.057). WELL's P/S Ratio (12.837) is slightly higher than the industry average of (5.986).

Industry description

The industry includes companies that publish and market books and magazines/periodicals. John Wiley & Sons, Inc., Meredith Corporation and Scholastic Corporation are some of the biggest companies in this industry. Like many other industries, publishing companies have branched out into online/digital publications (while retaining their original print business), to capture the burgeoning market in electronic media. Business could be cyclical in certain cases, since weak consumer sentiment during an economic downturn might depress sales of some magazines and books.

Market Cap

The average market capitalization across the Publishing: Books/Magazines Industry is 16.28B. The market cap for tickers in the group ranges from 113.09K to 162.86B. WELL holds the highest valuation in this group at 162.86B. The lowest valued company is DIGI at 113.09K.

High and low price notable news

The average weekly price growth across all stocks in the Publishing: Books/Magazines Industry was -3%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 7%. NHPBP experienced the highest price growth at 11%, while CHCT experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Publishing: Books/Magazines Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 108% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 28
P/E Growth Rating: 74
Price Growth Rating: 47
SMR Rating: 81
Profit Risk Rating: 64
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
WELL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a real estate investment trust

Industry PublishingBooksMagazines

Profile
Details
Industry
Real Estate Investment Trusts
Address
4500 Dorr Street
Phone
+1 419 247-2800
Employees
533
Web
http://www.welltower.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.